Published in Cancer Res on November 01, 1985
Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One (2007) 2.77
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J (1989) 1.84
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A (1995) 1.56
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A (1986) 1.54
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell (1992) 1.50
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer (1999) 1.38
HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol (1996) 1.35
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci U S A (1989) 1.21
Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol (1991) 1.20
Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol (1994) 1.11
DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro Oncol (2014) 1.10
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
Brain metastases in melanoma: roles of neurotrophins. Neuro Oncol (2004) 1.07
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med (1988) 1.00
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther (2009) 1.00
BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99
Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLoS Biol (2014) 0.98
Induction of nerve growth factor receptors on cultured human melanocytes. Proc Natl Acad Sci U S A (1988) 0.98
Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol (1990) 0.97
Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer (2008) 0.97
Metastasis suppressor NM23-H1 promotes repair of UV-induced DNA damage and suppresses UV-induced melanomagenesis. Cancer Res (2011) 0.94
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol (1996) 0.92
Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol Biol Cell (1993) 0.92
Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. PLoS One (2011) 0.91
Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem (2009) 0.90
Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. Br J Cancer (1995) 0.90
Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. Pigment Cell Melanoma Res (2011) 0.87
Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother (2008) 0.87
Involvement of the ALL-1 gene in a solid tumor. Proc Natl Acad Sci U S A (1995) 0.87
Developmental pathways activated in melanocytes and melanoma. Arch Biochem Biophys (2014) 0.84
Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res (2010) 0.84
A cell culture study on melanocytes from patients with neurofibromatosis-1. Arch Dermatol Res (1989) 0.83
Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer (2000) 0.83
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res (2015) 0.82
Identification of genes potentially regulated by human polynucleotide phosphorylase (hPNPase old-35) using melanoma as a model. PLoS One (2013) 0.81
Melanoma cells homing to the brain: an in vitro model. Biomed Res Int (2015) 0.80
Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience (2014) 0.80
Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. Front Nutr (2016) 0.78
Flexible, actin-based ridges colocalise with the beta1 integrin on the surface of melanoma cells. Br J Cancer (2005) 0.77
Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. Biomaterials (2015) 0.77
Establishment and characterization of a clear-cell sarcoma (malignant melanoma of soft parts) cell line. Arch Dermatol Res (1994) 0.77
A murine monoclonal antibody, MoAb HMSA-5, against a melanosomal component highly expressed in early stages, and common to normal and neoplastic melanocytes. Br J Cancer (1993) 0.76
Metastatic melanoma cells evade immune detection by silencing STAT1. Int J Mol Sci (2015) 0.75
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies. Cancer Lett (2014) 0.75
Moles and melanoma--new method in the madness. West J Med (1994) 0.75
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci (2016) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
THE CLINICAL EVALUATION OF AUREOMYCIN. J Clin Invest (1949) 3.60
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med (1989) 3.03
Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol (1978) 2.81
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res (2001) 2.47
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med (1993) 2.24
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A (1982) 2.15
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc (1999) 1.96
Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med (1991) 1.95
The developmental biology of primary human malignant melanomas. Semin Oncol (1975) 1.92
Premarital sex, schoolgirl pregnancy, and school quality in rural Kenya. Stud Fam Plann (2001) 1.91
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res (1994) 1.86
Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J (1989) 1.84
Carbohydrate-specific adhesion of bacteria to thin-layer chromatograms: a rationalized approach to the study of host cell glycolipid receptors. Anal Biochem (1985) 1.78
Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood (1987) 1.77
Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol (1982) 1.76
Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res (2001) 1.75
Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA (1978) 1.74
Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Extraadrenal myelolipoma: MR imaging findings. AJR Am J Roentgenol (1998) 1.73
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A (1999) 1.68
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A (1993) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst (1998) 1.61
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene (2001) 1.59
Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol (1979) 1.59
Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res (1984) 1.58
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57
Action spectrum for retinal injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol (1982) 1.56
Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res (1998) 1.55
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A (1986) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A (1984) 1.52
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med (1977) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
Primary malignant melanoma of the urinary bladder. Cancer (1976) 1.48